CN105949241B - 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 - Google Patents
一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 Download PDFInfo
- Publication number
- CN105949241B CN105949241B CN201610493276.7A CN201610493276A CN105949241B CN 105949241 B CN105949241 B CN 105949241B CN 201610493276 A CN201610493276 A CN 201610493276A CN 105949241 B CN105949241 B CN 105949241B
- Authority
- CN
- China
- Prior art keywords
- crystal formation
- sodium salts
- oxazolidinone antibacterials
- antibacterials
- suo shu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 39
- 229940088710 antibiotic agent Drugs 0.000 title claims abstract description 38
- 239000013078 crystal Substances 0.000 title claims abstract description 38
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 36
- 159000000000 sodium salts Chemical class 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000003115 biocidal effect Effects 0.000 claims abstract description 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 238000005755 formation reaction Methods 0.000 description 23
- 238000000034 method Methods 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 150000001875 compounds Chemical group 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- -1 azoles amine Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610493276.7A CN105949241B (zh) | 2016-06-24 | 2016-06-24 | 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 |
PCT/CN2016/090283 WO2017096907A1 (zh) | 2016-06-24 | 2016-07-18 | 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610493276.7A CN105949241B (zh) | 2016-06-24 | 2016-06-24 | 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105949241A CN105949241A (zh) | 2016-09-21 |
CN105949241B true CN105949241B (zh) | 2018-01-12 |
Family
ID=56901652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610493276.7A Expired - Fee Related CN105949241B (zh) | 2016-06-24 | 2016-06-24 | 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN105949241B (zh) |
WO (1) | WO2017096907A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749321B (zh) * | 2017-01-17 | 2018-10-09 | 浙江普洛得邦制药有限公司 | 一种噁唑烷酮类抗菌药物钠盐的晶型b及其制备方法和应用 |
CN107353305A (zh) * | 2017-07-12 | 2017-11-17 | 浙江普洛得邦制药有限公司 | 一种噁唑烷酮类抗菌药物的三羟甲基氨基甲烷盐及其晶型a、制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103896963A (zh) * | 2012-12-26 | 2014-07-02 | 中国科学院上海药物研究所 | 苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 |
CN106083837A (zh) * | 2016-05-27 | 2016-11-09 | 浙江普洛得邦制药有限公司 | 一种噁唑烷酮类抗菌药物及其中间体的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100360525C (zh) * | 2004-09-16 | 2008-01-09 | 中国科学院上海药物研究所 | 一类新的噁唑烷酮衍生物、其制备方法和用途 |
CN102260277B (zh) * | 2010-05-24 | 2013-07-24 | 中国科学院上海药物研究所 | 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 |
-
2016
- 2016-06-24 CN CN201610493276.7A patent/CN105949241B/zh not_active Expired - Fee Related
- 2016-07-18 WO PCT/CN2016/090283 patent/WO2017096907A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103896963A (zh) * | 2012-12-26 | 2014-07-02 | 中国科学院上海药物研究所 | 苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 |
CN106083837A (zh) * | 2016-05-27 | 2016-11-09 | 浙江普洛得邦制药有限公司 | 一种噁唑烷酮类抗菌药物及其中间体的制备方法 |
Non-Patent Citations (1)
Title |
---|
Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyloxazolidinones Leading to a Promising Antibacterial Agent;Bin Guo et al.;《J. Med. Chem.》;20130221;第56卷;page: 2642-2650 * |
Also Published As
Publication number | Publication date |
---|---|
CN105949241A (zh) | 2016-09-21 |
WO2017096907A1 (zh) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10954223B2 (en) | Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof | |
EP3549932B1 (en) | Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof | |
EA036131B1 (ru) | Способ получения аморфного летермовира | |
WO2017080290A1 (en) | Complex of angiotensin receptor antagonist and neutral endopeptidase inhibitor | |
US20220144851A1 (en) | Novel polymorphs of integrase inhibitor | |
CN105949241B (zh) | 一种噁唑烷酮类抗菌药物钠盐的晶型a及其制备方法和应用 | |
US20190241530A1 (en) | Crystal form of ozanimod, and preparation method and pharmaceutical composition thereof | |
TWI727314B (zh) | 盛格列汀的鹽、其製備方法與用途以及藥物組合物 | |
CN102898438B (zh) | 哌拉西林钠与舒巴坦钠共晶及其制备方法、以及包含该共晶的药物组合物及其应用 | |
CN106478723B (zh) | 一种噁唑烷酮类抗菌药物的晶型b及其制备方法和应用 | |
CN106632481B (zh) | 一种噁唑烷酮类抗菌药物的晶型a及其制备方法和应用 | |
CN104892584B (zh) | 一种阿法替尼双马来酸盐无定型态及其制备方法、制剂 | |
HUE030504T2 (en) | Process for the preparation of ralfinamide methanesulfonate salts or their R-enantiomers | |
CN102256951B (zh) | 结晶水合物、药物组合物及其用途 | |
WO2019129100A1 (zh) | 一种Valbenazine二对甲苯磺酸盐的晶型及其制备方法和用途 | |
CN113896649B (zh) | 一种丙胺卡因晶型及制备方法 | |
CN104603141B (zh) | 哌拉西林钠与舒巴坦钠共晶及其制备方法、以及包含该共晶的药物组合物及其应用 | |
CN112986289A (zh) | 一种阿莫西林胶囊的一致性评价检测方法 | |
US20190135848A1 (en) | Amine solvate of sodium-glucose linked transporter inhibitor, and preparation method and application thereof | |
CN109776543A (zh) | 依鲁替尼盐、其晶体、制备方法、药物组合物及应用 | |
CN108250257B (zh) | 双硫酸卡那霉素水合物及其制法 | |
Freitas et al. | Using thermal analysis as quality control for famotidine polymorph contamination | |
CN109875970B (zh) | 阿奇霉素固体制剂及其制备方法 | |
CN107793472A (zh) | 奥利万星二磷酸盐的晶型及其制备方法和用途 | |
CN113603642A (zh) | 硫酸羟氯喹水合物、其晶型、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180726 Address after: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai Patentee after: Shanghai Institute of Materia Medica, Chinese Academy of Sciences Address before: 322118 Jiangnan Road, Hengdian Industrial Zone, Dongyang, Jinhua, Zhejiang 519 Co-patentee before: YOSEMADE PHARMACEUTICAL CO., LTD. Patentee before: Zhejiang Puluo Debang Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180112 Termination date: 20190624 |
|
CF01 | Termination of patent right due to non-payment of annual fee |